ESR1 and breast cancer: Other KAT6 inhibitors are showing favorable PK and safety profiles in preclinical cell lines and animal models of ER+/HER2− breast cancer [200, 201, 202, 203, 204], which may offer a promising avenue for entering in‐human clinical trials and provide a therapeutic choice for these patients.